Ustekinumab-aekn Injection, Solution
Product Images NDC 51759-413

Product Visual Gallery

This gallery contains 23 technical images submitted to the FDA as part of the official labeling for Ustekinumab-aekn (NDC 51759-413). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (Image 1)

A line graph showing patient response percentages over 24 weeks for placebo, Ustekinumab 45 mg, and Ustekinumab 90 mg subcutaneous injections. The graph compares three groups, illustrating a higher percentage of patients responding over time with Ustekinumab 90 mg, followed by 45 mg, and lowest with placebo.*

FDA Label Image

Image (Image 10)

An instructional illustration showing a hand using a fingertip to press on a rounded object, demonstrating a step likely related to injection preparation or administration for Ustekinumab-aekn subcutaneous injection.*

FDA Label Image

Image (Image 11)

Illustration labeled Figure J showing a single-dose injection device positioned above a container filled with an ice bath, indicated by a downward arrow. A stirring rod is present in the ice bath, suggesting a cooling or preparation step for the injection solution.*

FDA Label Image

Image (Image 12)

Illustration showing items related to Ustekinumab-aekn injection preparation and administration. It includes an adhesive bandage, antiseptic wipes, cotton ball or gauze pads, a Ustekinumab-aekn vial, a syringe with attached needle, and an FDA-cleared sharps disposal container, each labeled accordingly.*

FDA Label Image

Image (Image 13)

Illustration showing recommended subcutaneous injection sites for Ustekinumab-aekn injection, solution. Highlighted areas include the front thigh, upper arm, lower abdomen, and buttocks as injection sites on a human figure.*

FDA Label Image

Image (Image 14)

An instructional illustration labeled Figure C, showing a vial with a partially removed or tilted cap indicated by an orange arrow, suggesting how to open the vial cap before use.*

FDA Label Image

Image (Image 15)

An instructional illustration showing two hands removing a protective cap from a vial, likely demonstrating preparation steps for administering a subcutaneous injection of Ustekinumab-aekn. The image highlights hand positioning and the motion of lifting the cap off the vial.*

FDA Label Image

Image (Image 16)

An instructional diagram labeled as Figure E showing two hands holding a syringe and a cap, illustrating the action of pulling the cap off the syringe by pulling in opposite directions.*

FDA Label Image

Image (Image 17)

An instructional illustration labeled Figure F depicting two hands preparing a syringe, with one hand holding a vial and the other drawing liquid from the vial into the syringe, demonstrating a step in medication preparation for injection.*

FDA Label Image

Image (Image 18)

An instructional illustration depicting two hands drawing liquid from a vial into a syringe, demonstrating preparation of a subcutaneous injection for the drug Ustekinumab-aekn injection solution by Teva Pharmaceuticals USA, Inc.*

FDA Label Image

Image (Image 19)

An instructional illustration showing two hands preparing a syringe for injection. One hand holds a vial inverted above the syringe to draw medication, while the other hand holds the syringe and is pressing the plunger to fill it. This image is relevant to the preparation of Ustekinumab-aekn injection solution for subcutaneous use.*

FDA Label Image

Image (Image 2)

An illustration of a subcutaneous injection device for ustekinumab-aekn showing labeled parts including plunger head, plunger, needle guard activation clips, needle guard wings, body, viewing window, label, needle, and needle cover. The diagram provides a detailed view of the injection mechanism components.*

FDA Label Image

Image (Image 20)

An instructional diagram showing the proper subcutaneous injection technique at a 45-degree angle. The image depicts a hand holding a syringe administering an injection into the skin of a forearm or thigh, demonstrating correct needle insertion angle.*

FDA Label Image

Image (Image 21)

An instructional diagram showing a hand holding a syringe at an approximately 45-degree angle to the skin surface, with an arrow pointing to the syringe needle. The illustration indicates the technique for administering a subcutaneous injection.*

FDA Label Image

Image (Image 22)

The image shows the packaging label for Ustekinumab-aekn Injection, 45 mg/0.5 mL, a subcutaneous injection solution by Teva Pharmaceuticals USA, Inc. The label includes the product name, strength, dosage form, route of administration, a single-dose prefilled syringe notice, and Teva logo. The label also has a barcode and regulatory text.*

FDA Label Image

Image (Image 23)

Packaging label for Ustekinumab-aekn Injection 90 mg/mL, a subcutaneous injection solution by Teva Pharmaceuticals USA, Inc. The label indicates it is a single-dose prefilled syringe and includes product strength, route, NDC 51759-414-32, and barcode. The label features the Teva logo and dosage instructions for the pharmacist.*

FDA Label Image

Image (Image 3)

An instructional figure labeled Figure B showing five items: an adhesive bandage, antiseptic wipes, a cotton ball or gauze pad, a Ustekinumab-aekn prefilled syringe, and an FDA-cleared sharps disposal container. The illustration visually identifies supplies typically used together for administration and safe disposal of a subcutaneous injection.*

FDA Label Image

Image (Image 4)

Illustration labeled 'Figure C' showing recommended injection sites for Ustekinumab-aekn solution. Yellow highlighted areas on a human figure include the front thigh, upper arm, abdomen, and buttocks, indicating appropriate subcutaneous injection locations.*

FDA Label Image

Image (Image 5)

An instructional illustration showing a hand removing the cap from a syringe prior to injection, with an arrow indicating the removal direction. This image relates to the preparation of an injection for a subcutaneous dosage form such as ustekinumab-aekn injection solution.*

FDA Label Image

Image (Image 6)

Illustration labeled Figure E showing a hand holding a syringe with a plunger being depressed. The syringe contains a liquid and is positioned for an injection, indicating subcutaneous administration technique.*

FDA Label Image

Image (Image 7)

An instructional illustration labeled "Figure F" depicting a hand administering a subcutaneous injection with a syringe. The syringe is held at a 45-degree angle to the skin, indicated by an arrow and angle symbol, demonstrating the proper injection technique.*

FDA Label Image

Image (Image 8)

An instructional illustration showing a hand holding a Ustekinumab-aekn prefilled syringe at an angle, with the needle inserted into the skin, demonstrating the subcutaneous injection technique.*

FDA Label Image

Image (Image 9)

An instructional illustration showing a hand holding a prefilled syringe with a needle shield being removed. The syringe appears to be prepared for subcutaneous injection, with a finger stabilizing the injection area on the skin.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.